Adoptive cellular therapies: the current landscape
Maartje W. Rohaan(The Netherlands Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
November 23, 2018
Cited by 391
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
|Nature Medicine|2014|692
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2022|517